Sector News

Stryker to build new innovation centre in Cork

September 23, 2014
Life sciences
US medical technologies company Stryker is to build a new 44,000 square foot surgical innovation centre in Cork, which will combine all Ireland-based research and new product development activities and support functions within one purpose-built facility. Construction is set to commence in the last months of this year, with completion expected in Q4 2015.
 
“This state-of-the-art facility will drive innovation by giving us the ability to design, develop and test new products in conditions that mimic real life,” Stryker Instruments President Jim Heath said.
 
The innovation centre, which Stryker says will fuel future growth, will focus on the research and development of products, technologies and solutions to reduce surgical procedure time and healthcare costs while improving surgical precision and clinical outcomes in the areas of bone cutting, soft tissue dissection and adjacent areas across a broad spectrum of surgical specialities and procedures. It is being constructed with the support of the IDA.
 
Stryker says the facility will feature state-of-the-art R&D facilities for product design and process development and a customer experience laboratory that will allow engineers and surgeons to test and evaluate new ideas, technology and product designs in a simulated operating room and surgical environment.
Stryker first came to Ireland in 1998 and now employs over 2,200 people at four sites between Cork and Limerick, including over 150 people in research and development.
 
Source: Irish Times

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach